Ventyx Biosciences, Inc. (VTYX)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Ventyx Biosciences, Inc. (“Ventyx” or “the Company”) (NASDAQ: VTYX). Investors who purchased Ventyx securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Ventyx has violated federal securities laws.
Ventyx Investigation Details
On December 2, 2025, Ventyx issued a press release “provid[ing] an update to its ongoing Phase 2 study of VTX2735 in patients with recurrent pericarditis (‘RP’).” In relevant part, the Company’s Chief Executive Officer said that “[w]e are . . . revising our guidance for topline data release from the interim analysis of the Phase 2 RP trial to Q1 2026,” describing the shift as “provid[ing] us with an opportunity to introduce dose-ranging studies with our new once-daily or QD formulation in the current Phase 2 study while also expanding into Canada, EU and the UK, a strategy we feel will accelerate Phase 3 timelines.” Following this news, Ventyx’s stock price fell $1.44 per share, or 15.35%, to close at $7.94 per share on December 2, 2025.
What’s Next for Ventyx Investors?
If you are aware of any facts relating to this investigation or purchased Ventyx securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
No Cost to Ventyx Investors
We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC For Ventyx Securities Investigation?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace,” said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Contact Info
Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | [email protected]
Attorney advertising.
Prior results do not guarantee similar outcomes.